Life
FDA Reduces Public Advisory Meetings Amid Calls for Transparency
The FDA's decision to limit public advisory committee meetings raises concerns about transparency in health decision-making processes.
Editorial Staff
1 min read
The FDA has announced a reduction in the frequency of public advisory committee meetings, a move that may impact stakeholder engagement.
This decision comes at a time when there is increasing demand from the public for greater transparency in regulatory processes.
The implications of this reduction could affect the FDA's ability to incorporate diverse perspectives into its decision-making framework.